TY - JOUR
T1 - The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
AU - Mathavan, Sangeetha
AU - Chen-Tan, Nigel
AU - Arfuso, Frank
AU - Al-Salami, Hani
N1 - Publisher Copyright:
© 2015 Informa Healthcare USA, Inc.
PY - 2016/8/17
Y1 - 2016/8/17
N2 - Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDCA), has permeation-enhancing effects. Sodium alginate (SA) was used to microencapsulate G and CDCA to produce control (G-SA) and test (G-CDCA-SA) microcapsules. Both microcapsules showed uniform structure, morphology, and good stability profiles. CDCA reduced G-release at pH 7.8, while G-release was negligible at lower pH values in both microcapsules. CDCA incorporation resulted in less swelling and stronger microcapsules, suggesting improved stability.
AB - Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDCA), has permeation-enhancing effects. Sodium alginate (SA) was used to microencapsulate G and CDCA to produce control (G-SA) and test (G-CDCA-SA) microcapsules. Both microcapsules showed uniform structure, morphology, and good stability profiles. CDCA reduced G-release at pH 7.8, while G-release was negligible at lower pH values in both microcapsules. CDCA incorporation resulted in less swelling and stronger microcapsules, suggesting improved stability.
KW - artificial cell microencapsulation
KW - bile acids
KW - chenodeoxycholic acid
KW - diabetes
KW - gliclazide
UR - http://www.scopus.com/inward/record.url?scp=84982958580&partnerID=8YFLogxK
U2 - 10.3109/21691401.2015.1058807
DO - 10.3109/21691401.2015.1058807
M3 - Article
C2 - 26212118
AN - SCOPUS:84982958580
SN - 2169-1401
VL - 44
SP - 1508
EP - 1519
JO - Artificial Cells, Nanomedicine and Biotechnology
JF - Artificial Cells, Nanomedicine and Biotechnology
IS - 6
ER -
